Table 1.
Patient demographics and disease characteristics (Japanese ITT population)
|
Dacomitinib n = 40 |
Gefitinib n = 41 |
|
|---|---|---|
| Age, median (range), y | 66 (39‐82) | 67 (49‐86) |
| 18‐64, n (%) | 19 (47.5) | 15 (36.6) |
| 65‐74 | 13 (32.5) | 18 (43.9) |
| ≥75 | 8 (20.0) | 8 (19.5) |
| Sex, n (%) | ||
| Male | 15 (37.5) | 20 (48.8) |
| Female | 25 (62.5) | 21 (51.2) |
| ECOG performance status, n (%) | ||
| 0 | 28 (70.0) | 21 (51.2) |
| 1 | 12 (30.0) | 20 (48.8) |
| Disease stage, n (%) | ||
| IIIB | 1 (2.5%) | 1 (2.4%) |
| IV | 38 (95%) | 40 (97.6%) |
| Unknown | 1 (2.5%) | 0 |
| Smoking status, n (%) | ||
| Never | 19 (47.5) | 24 (58.5) |
| Former | 20 (50.0) | 16 (39.0) |
| Current | 1 (2.5) | 1 (2.4) |
| EGFR mutation status, n (%) | ||
| Exon 19 deletion | 26 (65.0) | 26 (63.4) |
| Exon 21 L858R mutation | 14 (35.0) | 15 (36.6) |
Cutoff date: July 29, 2016.
Abbreviation: ITT, intention‐to‐treat.